Codex DNA, Inc. (DNAY)
|Net Income (ttm)||n/a|
|Day's Range||11.76 - 13.55|
|52-Week Range||11.26 - 25.70|
|Price Target||26.50 (+121.2%)|
|Est. Earnings Date||Nov 9, 2021|
Codex DNA is a leading synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. A key part of our solution is our BioXp system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease-of-use and hands-free automation. We believe our BioXp system can democratize synthetic biology by simplifying the process of building DNA and mR... [Read more...]
In 2020, Codex DNA's revenue was $6.58 million, an increase of 36.86% compared to the previous year's $4.81 million. Losses were -$18.01 million, 116.9% more than in 2019.Financial Statements
SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June...
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), the pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2021 fin...
Codex DNA Inc (NASDAQ: DNAY) has announced a licensing and supply agreement with TriLink Biotechnologies, part of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) for CleanCap technology. Codex DNA wil...
Codex DNA Announces Licensing and Supply Deal with TriLink Biotechnologies for CleanCap® mRNA Capping Technology
Alliance to expand the range of therapeutic and vaccine applications for the BioXp™ system Alliance to expand the range of therapeutic and vaccine applications for the BioXp™ system
Codex DNA Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Addi...
SAN DIEGO, June 22, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY) today announced the closing of its initial public offering of 7,666,664 shares of common stock, including the full exercise of...
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (“Codex DNA”), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today ...
Codex DNA, Inc. (“Codex DNA”), creators of the BioXp™ system, a fully automated benchtop instrument that...
Codex DNA, Inc. has filed to go public with an IPO on the NASDAQ.